A Study of Duloxetine in the Treatment of Fibromyalgia

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: Boehringer Ingelheim
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Meet criteria for primary fibromyalgia syndrome as defined by the American College of Rheumatologists

Exclusion Criteria:

• Treatment with a monoamine oxidase inhibitor within 14 days prior to Visit 2 or the potential need to take within 5 days after discontinuation from the study.

• Any patients judged by their physicians to be at serious suicidal risk.

• Have uncontrolled narrow-angle glaucoma